Objective  To investigate the improvement effect of the combination of duloxetine and eszopiclone on sleep quality and quality of life in patients with depression complicated with insomnia.

Methods  A retrospective analysis was conducted on patients with depression and insomnia admitted to the Department of Psychosomatic Medicine of Lishui Second People's Hospital from January 2023 to December 2024. Patients were divided into a control group (duloxetine treatment) and a study group (duloxetine treatment combined with eszopiclone). The efficacy indicators of the patients were collected after 4 weeks of treatment, including clinical efficacy, sleep quality [Pittsburgh Sleep Quality Index (PSQI)], quality of life [Global Quality of Life Questionnaire (GQOLI-74)], depression [Beck Depression Inventory (BDI-II)] and adverse reactions.

Results  A total of 150 patients was enrolled, including 72 in the control group and 78 in the study group. The treatment efficacy rate was significantly higher in the study group than in the control group (89.74% vs. 76.39%, P<0.05). After treatment, PSQI and BDI-II scores decreased in both groups, while GQOLI-74 scores increased (P<0.05). Furthermore, PSQI and BDI-II scores in the study group were lower than those in the control group, while GQOLI-74 scores were higher (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion  Duloxetine combined with eszopiclone can significantly improve depression and insomnia symptoms, increase treatment efficacy, improve quality of life, and have good safety in patients with depression and insomnia. .

1.Huang YY, Gan YH, Yang L, et al. Depression in Alzheimer's disease: epidemiology, mechanisms, and treatment[J]. Biol Psychiatry, 2024, 95(11): 992-1005. DOI: 10.1016/j.biopsych.2023.10.008.

2.Dubovsky SL, Marshall D. Benzodiazepines remain important therapeutic options in psychiatric practice[J]. Psychother Psychosom, 2022, 91(5): 307-334. DOI: 10.1159/000524400.

3.Shigetsura Y, Imai S, Endo H, et al. Assessment of suvorexant and eszopiclone as alternatives to benzodiazepines for treating insomnia in patients with major depressive disorder[J]. Clin Neuropharmacol, 2022, 45(3): 52-60. DOI: 10.1097/WNF.0000000000000499.

4.Rathbun AM, Mehta R, Ryan AS, et al. Duloxetine plus exercise for knee osteoarthritis and depression: a feasibility study[J]. Osteoarthr Cartil Open, 2023, 6(1): 100426. DOI: 10.1016/j.ocarto.2023.100426.

5.Sweetman A, Lack L, Van Ryswyk E, et al. Co-occurring depression and insomnia in Australian primary care: recent scientific evidence[J]. Med J Aust, 2021, 215(5): 230-236. DOI: 10.5694/mja2.51200.

6.Sochal M, Witkowska A, Binienda A, et al. The effect of serotonin transmission on depressive and insomnia symptoms in inflammatory bowel diseases[J]. J Clin Med, 2023, 12(19): 6353. DOI: 10.3390/jcm12196353.

7.Mei J, Wang Y, Song X, et al. The needle in the haystack: identifying and validating common genes of depression, insomnia, and inflammation[J]. J Affect Disord, 2023, 342: 45-53. DOI: 10.1016/j.jad.2023.08.127.

8.Mirchandaney R, Barete R, Asarnow LD. Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes[J]. Curr Psychiatry Rep, 2022, 24(2): 121-128. DOI: 10.1007/s11920-022-01326-3.

9.Tandon VR, Sharma S, Mahajan A, et al. Menopause and sleep disorders[J]. J Midlife Health, 2022, 13(1): 26-33. DOI: 10.4103/jmh.jmh_18_22.

10.刘晓华, 彭代辉, 王韵, 等. 伴焦虑痛苦特征抑郁症的临床诊治专家共识[J]. 精神医学杂志, 2021, 34(1): 74-78. [Liu  XH, Peng DH, Wang Y, et al. Expert consensus on the clinical diagnosis and treatment of depression with anxious distress features[J]. Journal of Psychiatry, 2021, 34(1): 74-78.] DOI: 10.3969/j.issn.2095-9346.2021.01.018.

11.中国民族医药学会睡眠分会. 中国民族医药治疗成人失眠的专家共识[J]. 北京中医药大学学报, 2022, 45(1): 21-28. [Sleep Branch of the Chinese Society of Ethnic Medicine. Expert consensus on the treatment of adult insomnia with Chinese ethnic medicine[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(1): 21-28.] DOI: 10.3969/j.issn.1006-2157.2022.01.004.

12.Hiemke C, Bergemann N, Clement HW, 等. 神经精神药理学治疗药物监测共识指南: 2017版[J]. 实用药物与临床, 2022, 25(1): 1-20. [Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: 2017 edition[J]. Practical Pharmacy and Clinical Remedies, 2022, 25(1): 1-20.] DOI: 10.14053/j.cnki.ppcr.202201001.

13.Gray JS, Petros T, Stupnisky R. Confirmatory factor analysis of beck depression inventory-II with two american indian samples[J]. Am J Orthopsychiatry, 2023, 93(4): 316-320. DOI: 10.1037/ort0000672.

14.Zitser J, Allen IE, Falgàs N, et al. Pittsburgh sleep quality index (PSQI) responses are modulated by total sleep time and wake after sleep onset in healthy older adults[J]. PLoS One, 2022, 17(6): e0270095. DOI: 10.1371/journal.pone.0270095.

15.Irwin MR, Carrillo C, Sadeghi N, et al. Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial[J]. JAMA Psychiatry, 2022, 79(1): 33-41. DOI: 10.1001/jamapsychiatry.2021.3422.

16.Teaima M, Yasser M, Elfar N, et al. Construction of sublingual trilaminated eszopiclone fast dissolving film for the treatment of insomnia: formulation, characterization and in vivo clinical comparative pharmacokinetic study in healthy human subjects[J].PLoS One, 2022, 17(6): e0266019. DOI: 10.1371/journal.pone.0266019.

17.Lin WC, Winkelman JW. Insomnia and treatment-resistant depression[J]. Prog Brain Res, 2023, 281: 115-129. DOI: 10.1016/bs.pbr.2023.01.005.

18.Le PH, Le LKD, Rajaratnam SMW, et al. Quality of life impacts associated with comorbid insomnia and depression in adult population[J]. Qual Life Res, 2024, 33(12): 3283-3298. DOI: 10.1007/s11136-024-03793-y.

19.Braillon A, Fried EI, Cristea IA, et al. Treatments for major depression[J]. Lancet, 2023, 401(10394): 2110. DOI: 10.1016/S0140-6736(23)00953-4.

20.Maciaszek J, Pawłowski T, Hadryś T, et al. The impact of the CYP2D6 and CYP1A2 gene polymorphisms on response to duloxetine in patients with major depression[J].Int J Mol Sci, 2023, 24(17): 13459. DOI: 10.3390/ijms241713459.